ACIP
February 22-24, 2023
ACIP meetings are virtual. No registration is required to watch the webcasts.
1600 Clifton Road, N.E., Mailstop H24-8
Atlanta, GA 30329-4027
acip@cdc.gov
To receive email updates about this page, enter your email address:
October 2022
ACIP approved the following recommendations by majority vote at its October 19-20, 2022 meeting:
- Approve the Recommended Child and Adolescent Immunization Schedule, United States, 2023 and Recommended Adult Immunization Schedule, United States, 2023.
- Adults with an immunocompromising condition, cochlear implant, or cerebrospinal fluid leak who have received both PCV13 and PPSV23 with incomplete vaccination status are recommended to complete their pneumococcal vaccine series by receiving either a dose of PCV20 at least 5 years after the last pneumococcal vaccine dose or PPSV23 as previously recommended.
- Shared clinical decision-making is recommended regarding administration of PCV20 for adults aged ≥65 years who completed their vaccine series with both PCV13 and PPSV23. If a decision to administer PCV20 is made, a dose of PCV20 is recommended at least 5 years after the last pneumococcal vaccine dose.
- Adults who have received PCV13 only are recommended to receive a dose of PCV20 at least 1 year after the PCV13 dose or PPSV23 as previously recommended to complete their pneumococcal vaccine series.
These recommendations have been adopted by the CDC Director and are now official. They will be published in MMWR in the coming months.
How are CDC vaccine recommendations developed, and what is the role of the ACIP? In this educational video, you’ll learn the purpose of the Advisory Committee on Immunization Practices (ACIP), its role in developing vaccine recommendations, and the process of vaccine recommendation development and approval.